Innovative Bispecific Nanobody Targeting ALB and VEGF for Cancer Therapy

VHH-P237 is a humanized nanobody-based bispecific fusion protein targeting albumin (ALB) and vascular endothelial growth factor (VEGF), currently in the Biological Testing stage of development. Designed for the potential treatment of cancer, VHH-P237 combines a single-domain antibody that targets ALB with two units of anti-VEGF nanobodies, all fused in tandem. This sophisticated construct leverages human embryonic kidney cell expression to maximize biocompatibility and efficiency. By simultaneously engaging ALB and VEGF, VHH-P237 aims to address key biological processes associated with tumor progression and therapeutic delivery.

Licensing Opportunity

VHH-P237 is available for out-licensing and collaborative development. We welcome partnership inquiries from biopharmaceutical companies interested in innovative nanobody-based therapeutics for oncology.

Development Phase

Modality

VHH-P237 employs an engineered bispecific antibody fusion format composed of a humanized single-domain antibody against ALB, linked via G2S peptide spacers to two anti-VEGF VHH domains. This modular nanobody architecture ensures a small molecular footprint and robust structural stability. The single-domain antibody format offers superior tissue penetration, rapid distribution, and excellent manufacturability. This enhanced pharmacokinetic profile, combined with dual targeting, provides significant advantages in treating cancer by enabling improved tumor access and sustained bioactivity in complex tumor microenvironments.

Target

ALB and VEGF are critical molecular targets in cancer biology. ALB, a predominant plasma protein, plays roles in maintaining oncotic pressure and drug transport, and is broadly expressed in the circulatory system. VEGF, as a key signaling protein, drives angiogenesis and is widely expressed in endothelial cells, with increased activity in the tumor microenvironment. Both ALB and VEGF are essential in cancer progression: ALB-binding extends therapeutic half-life, while antagonism of VEGF disrupts tumor neovascularization. Targeting ALB and VEGF simultaneously leverages their complementary roles, making VHH-P237 a strategically attractive asset for innovative cancer therapy development.

Mechanism of Action

VHH-P237 exerts its effect by binding ALB to enhance pharmacokinetics and targeting VEGF to inhibit pathological angiogenesis pivotal for tumor growth. Acting as an angiogenesis inhibitor and signal transduction modulator, the nanobody construct disrupts VEGF-driven vessel formation and restricts nutrient supply to malignancies. Its dual-target platform, enabled by the modular nanobody scaffold, opens the door for versatile therapeutic applications, including further development into bispecific, multispecific, or antibody-drug conjugate formats to address the evolving landscape of cancer therapies.

Cancer

Cancer represents a leading cause of morbidity and mortality worldwide, with a growing global burden across developed and developing countries. Its multifaceted pathogenesis involves genetic, epigenetic, and environmental factors, leading to the transformation of normal cells into malignant ones. Current standard-of-care approaches include surgery, chemotherapy, radiation therapy, as well as targeted and immune-based therapies. However, challenges such as drug resistance, tumor heterogeneity, excessive toxicity, and limited efficacy in solid tumors persist. There remains a substantial unmet need for innovative, precise, and less toxic therapeutic options. VHH-P237, by targeting both ALB for improved pharmacological properties and VEGF to inhibit angiogenesis, offers promising potential to complement and advance cancer treatment paradigms.